**Ruxolitinib Non-Interventional Prospective Study**

Effect of prior therapy with JAK inhibitor ruxolitinib in patients with primary or post ET/PMF myelofibrosis on outcome after allogeneic stem cell transplantation

In this prospective, non-interventional study the impact of ruxolitinib treatment prior to allo-HSCT on outcome such as engraftment, graft-versus-host disease, non-relapse mortality, relapse and overall survival will be addressed. Secondary outcomes are treatment-related toxic effects, relapse rate, event-free survival and overall survival. Patients’ outcome will be analysed also by response status to ruxolitinib prior to HSCT. The paper is expected in 2019/2020.

**Number of patients needed**

100 in 2 years (the participation form is available at the EBMT booth)

**Inclusion criteria**

All patients with primary or post ET/PMF myelofibrosis who undergo allogeneic stem cell transplantation and have been previously treated with ruxolitinib, regardless of their response to this drug.

**Exclusion criteria**

Blastic phase of myelofibrosis

**Principal investigator**

Nicolaus Kröger, University Medical Center Hamburg-Eppendorf, Germany

**Contact**

Spencer Novartis

---

**CMWP Publications**
